Advantagene Reaches Enrollment Goal in Phase 2 Trial Testing Prostate Cancer Vaccine

Advantagene Reaches Enrollment Goal in Phase 2 Trial Testing Prostate Cancer Vaccine
Advantagene, also known as Candel Therapeutics, has reached its patient enrollment goal in an ongoing Phase 2 trial testing the effectiveness of ProstAtak, the company’s prostate cancer vaccine, among men with localized prostate cancer who chose to remain on active surveillance. ProstAtack is a gene-mediated cytotoxic immunotherapy (GMCI). That's a type of low-toxicity immunotherapy that stimulates patients' immune systems to build up a strong immune response against cancer, much like a vaccine. It is based on the combination of aglatimagene besadenovec — a viral vector that infects cancer cells with the herpes simplex virus — and oral valacyclovir, an antiviral drug. The combo kills cancer cells and, at the same time, triggers an immune response against them. The effectiveness of ProstAtak among patients with localized prostate cancer who chose active surveillance — close monitoring of cancer progression — as their primary form of treatment is currently being assessed in the randomized, double-blind, placebo-controlled, ULYSSES Phase 2 trial (NCT02768363). The trial has reached its patient enrollment goal, with 190 participants recruited from 22 different clinical centers in the U.S. and Mexico. The study has been
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *